157 related articles for article (PubMed ID: 1620653)
1. Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice.
Hirosue Y; Inui A; Miura M; Nakajima M; Okita M; Himori N; Baba S; Kasuga M
Peptides; 1992; 13(1):155-7. PubMed ID: 1620653
[TBL] [Abstract][Full Text] [Related]
2. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
O'Neill MF; Dourish CT; Iversen SD
Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
[TBL] [Abstract][Full Text] [Related]
3. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
Vasar E; Lang A; Harro J; Bourin M; Bradwejn J
Neuropharmacology; 1994 Jun; 33(6):729-35. PubMed ID: 7936110
[TBL] [Abstract][Full Text] [Related]
4. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism.
Crawley JN; Fiske SM; Durieux C; Derrien M; Roques BP
J Pharmacol Exp Ther; 1991 Jun; 257(3):1076-80. PubMed ID: 2046021
[TBL] [Abstract][Full Text] [Related]
5. Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.
Vasar E; Stephenson JD; Meldrum BS
Eur J Pharmacol; 1991 Sep; 202(3):385-90. PubMed ID: 1748160
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice.
Hirosue Y; Inui A; Teranishi A; Miura M; Nakajima M; Okita M; Nakajima Y; Himori N; Baba S; Kasuga M
Am J Physiol; 1993 Sep; 265(3 Pt 2):R481-6. PubMed ID: 8214137
[TBL] [Abstract][Full Text] [Related]
7. [Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in amygdala of the rat].
Pu SF; Han JS
Sheng Li Xue Bao; 1993 Oct; 45(5):470-8. PubMed ID: 8146670
[TBL] [Abstract][Full Text] [Related]
8. Activation of CCK-A receptors induces elevation of plasma corticosterone in rats.
Katsuura G; Ibii N; Matsushita A
Peptides; 1992; 13(1):203-5. PubMed ID: 1620654
[TBL] [Abstract][Full Text] [Related]
9. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
Crawley JN
J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584
[TBL] [Abstract][Full Text] [Related]
10. The effect of centrally administered CCK-receptor antagonists on food intake in rats.
Corp ES; Curcio M; Gibbs J; Smith GP
Physiol Behav; 1997 Jun; 61(6):823-7. PubMed ID: 9177553
[TBL] [Abstract][Full Text] [Related]
11. Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse.
Vasar E; Harro J; Lang A; Pôld A; Soosaar A
Psychopharmacology (Berl); 1991; 105(3):393-9. PubMed ID: 1798834
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin octapeptide decreases food intake in white-crowned sparrows.
Richardson RD; Boswell T; Weatherford SC; Wingfield JC; Woods SC
Am J Physiol; 1993 May; 264(5 Pt 2):R852-6. PubMed ID: 8498593
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice.
Derrien M; Noble F; Maldonado R; Roques BP
Neurosci Lett; 1993 Oct; 160(2):193-6. PubMed ID: 8247353
[TBL] [Abstract][Full Text] [Related]
14. Type-A CCK receptors mediate the inhibition of food intake and activity by CCK-8 in 9- to 12-day-old rat pups.
Smith GP; Tyrka A; Gibbs J
Pharmacol Biochem Behav; 1991 Jan; 38(1):207-10. PubMed ID: 2017446
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
Millington WR; Mueller GP; Lavigne GJ
J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
[TBL] [Abstract][Full Text] [Related]
16. Modulatory role for CCK-B antagonists in Parkinson's disease.
Boyce S; Rupniak NM; Tye S; Steventon MJ; Iversen SD
Clin Neuropharmacol; 1990 Aug; 13(4):339-47. PubMed ID: 1976438
[TBL] [Abstract][Full Text] [Related]
17. Loxiglumide, L-364,718 and L-365,260 prevent the inhibition of spontaneous acetylcholine release from the frontal cerebral cortex of freely moving rat peripherally administered with cholecystokinin-8S.
Kimura I; Wakasono S; Kimura M
Jpn J Pharmacol; 1995 May; 68(1):129-32. PubMed ID: 7494376
[TBL] [Abstract][Full Text] [Related]
18. L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity.
Soar J; Hewson G; Leighton GE; Hill RG; Hughes J
Pharmacol Biochem Behav; 1989 Jul; 33(3):637-40. PubMed ID: 2587606
[TBL] [Abstract][Full Text] [Related]
19. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin.
Altar CA; Boyar WC
Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523
[TBL] [Abstract][Full Text] [Related]
20. Centrally administered CCK-8 suppresses activity in mice by a "peripheral-type" CCK receptor.
Britton DR; Yahiro L; Cullen MJ; Kerwin JF; Kopecka H; Nadzan AM
Pharmacol Biochem Behav; 1989 Dec; 34(4):779-83. PubMed ID: 2623030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
